Avecho Biotechnology Limited

As of December 31, 2025, Avecho Biotechnology Limited carries a market capitalization of 33.06M, placing it among publicly traded companies globally. Its enterprise value stands at 28.41M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Avecho Biotechnology Limited's next confirmed earnings release is scheduled for March 3, 2027.

As of December 31, 2025, Avecho Biotechnology Limited has 3.67B shares outstanding.

These figures are as of December 31, 2025. The price-to-sales ratio is 23.61, and the price-to-book ratio stands at 21.20.

These figures are as of December 31, 2025. The EV/Sales ratio of 22.82 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 28.41M versus a market cap of 33.06M, with the gap driven by net debt and cash on the balance sheet.

As of December 31, 2025, Avecho Biotechnology Limited maintains a current ratio of 9.95, meaning it holds 9.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.93, indicating moderate leverage, while an interest coverage ratio of -12.70 demonstrates limited ability to service its debt obligations.

Over the twelve months ended December 31, 2025, Avecho Biotechnology Limited posted a negative return on equity (ROE) of -182.91, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -72.98, reflecting losses generated across the asset base. Inventory turnover of 4.80 indicates how many times Avecho Biotechnology Limited sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on October 22, 2026, Avecho Biotechnology Limited's stock has gained approximately 150.00% over the past 52 weeks. The 50-day moving average sits at 0.02, while the 200-day moving average is 0.01.

Over the twelve months ended December 31, 2025, Avecho Biotechnology Limited generated 1.25M in revenue and converted that into -4.42M in net income, yielding earnings per share of 0.00. EBITDA reached -5.86M, while operating income came in at -6.00M.

As of December 31, 2025, Avecho Biotechnology Limited holds 4.66M in cash and equivalents against 14,473.00 in total debt, resulting in a net debt position of -4.66M. Total book value stands at 1.56M, with working capital of 6.35M providing operational flexibility.

Over the twelve months ended December 31, 2025, Avecho Biotechnology Limited posted a gross margin of 71.94, reflecting its pricing power and cost economics. The operating margin of -481.66 and net profit margin of -354.73 provide insight into operational efficiency.

These figures cover the twelve months ended December 31, 2025. Total shareholder yield is negative at -3.59, meaning Avecho Biotechnology Limited raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Avecho Biotechnology Limited's most recent stock split took place on September 29, 2017 with a 83:85 split ratio.

As of December 31, 2025, Avecho Biotechnology Limited has an Altman Z-Score of -51.91, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.